经尿道膀胱肿瘤等离子电切术治疗非肌层浸润性膀胱癌的效果研究

Effect of transurethral plasmakinetic resection of bladder tumor for the treatment of non-muscle-invasive bladder cancer

目的分析经尿道膀胱肿瘤等离子电切术治疗非肌层浸润性膀胱癌的临床效果。方法68例非肌层浸润性膀胱癌患者,随机分为对照组和试验组,各34例。对照组患者实施常规开放膀胱部分切除手术治疗,试验组患者采取经尿道膀胱肿瘤等离子电切术治疗。比较两组治疗效果、并发症发生率及手术时间、术中失血量、留置导尿管时间。结果两组缓解率比较差异无统计学意义(P>0.05)。试验组并发症发生率为2.94%,低于对照组的26.47%,差异有统计学意义(P<0.05)。试验组术中失血量(46.21±1.25)ml少于对照组的(98.56±2.91)ml,手术时间(45.21±5.21)min、留置导尿管时间(4.19±1.51)d均短于对照组的(93.56±12.91)min、(10.25±3.18)d,差异有统计学意义(P<0.05)。结论经尿道膀胱肿瘤等离子电切术治疗非肌层浸润性膀胱癌的临床效果确切,可减少并发症,减少出血,值得推广应用。

Objective To analyze the clinical effect of transurethral plasmakinetic resection of bladder tumor for the treatment of non-muscle-invasive bladder cancer.Methods A total of 68 patients with nonmuscle-invasive bladder cancer were randomly divided into control group and experimental group,with 34 cases in each group.Patients in the control group underwent conventional open partial cystectomy,and patients in the experimental group underwent transurethral plasmakinetic resection of bladder tumor.The therapeutic effect,complication rate,operation time,intraoperative blood loss,and indwelling catheter time were compared between the two groups.Results There was no statistically significant difference in remission rate between the two groups(P>0.05).The complication rate in the experimental group was 2.94%,which was lower than 26.47%in the control group,and the difference was statistically significant(P<0.05).The intraoperative blood loss(46.21±1.25)ml of the experimental group was less than(98.56±2.91)ml of the control group,and the operation time(45.21±5.21)min and indwelling catheter time(4.19±1.51)d were shorter than(93.56±12.91)min and(10.25±3.18)d of the control group.All differences were statistically significant(P<0.05).Conclusion Transurethral plasmakinetic resection of bladder tumor has definite clinical effect on the treatment of non-muscle-invasive bladder cancer,and it can reduce complications and bleeding,which is worthy of popularization and application.